Advertise on podcast: IMPACT Medicom

The Canadian Hematology Consensus Group, or CHCG, is a national collaboration of Canadian hematologists and healthcare professionals dedicated to improving patient care through the development of National consensus recommendations in hematologic malignancies. Our most recent consensus paper has  been published in Current Oncology. The paper provides treatment recommendations for hematologists managing patients with relapsed and/or refractory FL. In this episode, we will discuss the content of the paper with Dr Lemieux, who is a lead author and a member of the CHCG scientific committee.  Our Guest Dr Lemieux is a Hematologist at the CHU de Québec-Université Laval in Quebec city, Quebec and a Canadian expert in the treatment of follicular lymphoma. This podcast episode has been funded by Merck Canada.

Dr. Carolyn Owen, Chair of the Canadian Hematology Consensus Group (CHCG), introduces the CHCG and discusses its mission to develop evidence-based Canadian consensus recommendations in areas of unmet need in hematology. In this video, Dr. Owen highlights the group’s multidisciplinary expert panel, rigorous methodology, and current initiatives, including consensus papers on relapsed/refractory follicular lymphoma and first-line diffuse large B-cell lymphoma. The CHCG was founded by Anna Christofides, President of IMPACT Medicom Inc. and Founder & Managing Director of the CHCG, to provide the scientific and operational infrastructure required to develop high-quality Canadian consensus recommendations and support knowledge translation in hematology. Learn more about the CHCG: www.canadianconsensusgroup.com

In this episode with Dr Robert Puckrin, we discuss the unmet needs of double-exposed patients with CLL/SLL, as well as the current and novel treatments that can address this gap.  Our guest Dr. Puckrin is a Hematologist and Clinician Investigator at the Arthur Child Comprehensive Cancer Centre and Alberta Blood and Marrow Transplant Program. He is also a clinical assistant professor at the University of Calgary. Dr Puckrin has received honoraria for advisory boards and/or speaking engagements from Abbvie, Astrazeneca, BeOne, Eli Lilly, Incyte, Kite, Janssen,Pfizer, Roche, and Seagen. Please provide your feedback on this episode by filling out this quick survey at the following link: https://survey.decipherinc.com/survey/selfserve/53b/g00e/2511135 Funding for this episode was provided by Eli Lilly Canada. This information is intended solely for educational purposes and is not intended to promote the use of any Eli Lilly Canada medication. All materials or information provided by Eli Lilly Canada Inc. for this learning program comply with applicable regulatory standards.​ Editorial control of this learning program resides with the speaker within the parameters of the Innovative Medicines Canada Code and Eli Lilly Policy. Eli Lilly Canada supports discussion of its products consistent with the approved prescribing information in the product monograph. Any off-label discussion of products represents the personal opinion of the speaker.​

In this podcast episode, Dr. Dimitrios Coutsinos describes a video capsule series involving three educational videos of lung resections using minimally invasive video-assisted thoracic surgery (VATS) following neoadjuvant immunotherapy in patients with lung cancer.  Our Host: Dr. Dimitrios Coutsinos is a thoracic surgeon at Interior Health Authority and a professor at the University of British Columbia. Dr. Coutsinos has received honoraria for advisory board attendance from: AstraZeneca, Bristol Myers Squibb, Intuitive Surgica, Johnson and Johnson, Merck, and Roche. Video Capsule Series: To access the video capsule series, please visit: https://www.impactmedicom.com/video-capsules. This podcast episode and video capsule series was funded by Merck Canada. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com.

In this podcast episode, we discuss clinical trial updates in chronic lymphocytic leukemia from the 2025 European Hematology Association annual congress in Milan, Italy and the 18th International Conference on Malignant Lymphoma in Lugano, Switzerland. The discussion involves an analysis of the data from abstracts investigating combination and novel therapies for the treatment of CLL. Our Host: Dr. Constantine Tam is Head of Lymphoma Service at Alfred Health and Professor of Haematology at Monash University in Melbourne, Australia. Prior to joining Alfred, Dr. Tam completed a Leukemia Fellowship at MD Anderson Cancer Centre in Houston, Texas and served as Disease Group Lead for Low Grade Lymphoma and CLL at Peter MacCallum Cancer Centre & Royal Melbourne Hospital for over 10 years. He is the global lead for the BTK inhibitor zanubrutinib, overseeing its development from the first human dosed to international licensing studies. He also played key roles in the first global study of ibrutinib and venetoclax in CLL and the pivotal study of Tisagenlecleucel in diffuse large B-cell lymphoma. Our guests: Dr. John Gribben is Consultant Hematologist and Medical Oncologist at the Barts Cancer Institute, Barts NHS Trust and Professor in Medical Oncology at The London School of Medicine, Queen Mary University of London, in London, UK. Dr. Gribben trained in Haematology at University College London and in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, where he remained on the faculty for 17 years before returning to the UK. Dr. Gribben serves on many international committees, including as Chair of the international workshop for NHL, co-Chair of the international workshop for CART, and founding member of the CLL Research Consortium. He also serves as an executive board member of the European Hematology Association, where he previously served as President from 2019-2021. Dr. Stephan Stilgenbauer is professor of medicine and Medical Director of the Comprehensive Cancer Center Ulm (CCCU), Head Early Clinical Trials Unit (ECTU), and Head Division of CLL Dept. of Internal Medicine III at Ulm University, Germany. He received his medical training at Heidelberg Medical School, Germany, and was trained in internal medicine and hematology-oncology at the Universities of Heidelberg and Ulm. He spent a postdoctoral fellowship at the German Cancer Research Center (DKFZ) in Heidelberg. His research focus is on the molecular pathogenesis and evolution as well as development of novel treatment strategies in hematological malignancies. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/)

(FRENCH) In this podcast episode, which follows this introduction in French, Dr Christopher Lemieux summarizes a paper by Dr Abramson, et al. on the management of Peripheral Neuropathy Associated with Brentuximab Vedotin in the Frontline Treatment of classical Hodgkin Lymphoma. Our Guest Dr Lemieux is a Hematologist at the Centre hospitalier universitair de Québec-Université Laval. He is also a member of the immunocellular therapy network fellowship program at Université Laval. This podcast episode was sponsored by Pfizer Canada Inc. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma. Our Guest Dr. Michael Chu is a clinician scientist at the Cross Cancer Institute and an Associate Professor at the University of Alberta in Edmonton, Alberta. This podcast episode was sponsored by Pfizer Canada Inc. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Versha Banerji, a Canadian hematologist from Manitoba and Dr. Jennifer Brown, an internationally renowned hematologist from the United States, discuss data on the treatment of CLL presented at the American Society of Hematology (or ASH) meeting in San Diego, CA. The discussion involves an analysis of the data from 8 presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is put into the Canadian context, with key take-aways that are relevant to practice in Canada.  Our Guests: Dr. Versha Banerji is a hematologist at Max Rady College of Medicine at the University of Manitoba in Winnipeg, Manitoba. Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts. This podcast episode was sponsored by BeiGene Canada ULC. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL.  Our Guest: Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com This episode was funded by Eli Lilly, Canada.

In this podcast episode, three of Canada’s top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis of the data from 6 oral presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is put into the Canadian context, with key take-aways that are relevant to practice in Canada.  Our Guests: Dr. Versha Banerji from Max Rady College of Medicine at the University of Manitoba in Winnipeg, Manitoba chairs the meeting. Dr. Banerji is joined by Dr Sarit Assouline, from the Jewish General Hospital in Montreal, Quebec and Dr. Christopher Hillis, from McMaster University in Hamilton, Ontario. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/)

In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss  updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examined the efficacy and safety of sonrotoclax plus zanubrutinib for the treatment of R/R CLL.  Our Guest: Dr. Stephen Opat is the director of Clinical Haematology at Monash Health, founder and chair of the Australasian Lymphoma and Related Diseases Registry and lead investigator of the Melbourne Genomics Health Alliance Lymphoma Flagship. This podcast episode was sponsored by BeiGene Canada ULC. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer vaccines and new targeted therapies. Our Guest: Dr. Barbara Melosky Dr Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group and is creator and chair of the British Columbia Lung Cancer Biobank.  This podcast episode was sponsored by Sanofi Aventis Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker (pathologist) discuss the latest biomarkers that may inform treatment of upper GI cancer.  Our Guests: Dr. Christine Brezden-Masley Dr.  Brezden-Masley is a Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health System in Toronto, Canada. Dr. Catherine Streutker Dr.  Streutker is a Professor in the Department of Laboratory Medicine & Pathobiology at the University of Toronto. This podcast episode was sponsored by Merck Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule version: https://www.youtube.com/watch?v=uk5JEUjbkDE&t=127s.  Our Guest: Dr. S. Mark Taylor is a Facial Plastic and Reconstructive surgeon in Halifax, Nova Scotia. He is currently a Professor of Surgery at Dalhousie University. His expertise and clinical interest includes rhinoplasty/nasal surgery, eyelid surgery, management of facial paralysis, facial skin cancer, facial reconstruction, and surgery of the aging face. Note: The faculty for this program had full editorial control of the content. The following program was funded by Sanofi. Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this podcast episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant. Our guest: Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Note: The faculty for this program had full editorial control of the content. The following program was funded by Sanofi. Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com